Further milestone in Galapagos collaboration
e-therapeutics plc announces that it has met a key milestone in its collaboration with Galapagos NV ("Galapagos"), a commercial stage company specialized in the discovery and development of small molecule medicines with novel modes of action, with a focus on inflammation, fibrosis and kidney disease.
This milestone results in a payment from Galapagos. The objective of the collaboration between the Company and Galapagos, which was announced on 10 June 2020, is to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF) and other fibrotic indications.
Under the terms of the agreement, e-therapeutics is eligible to receive additional milestone payments through pre-clinical and clinical development as well as commercial milestones.
I am delighted with the progress of our collaboration with Galapagos following our recent update on 23 April 2021. We believe e-therapeutics' network biology approach will become an important component of small molecule drug discovery and we are implementing the same approach to our internal pipeline, using RNAi as the therapeutic modality of choice.
Ali Mortazavi
Chief Executive Officer
Market Abuse Regulation (MAR) Disclosure - Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.